Welcome to our dedicated page for Palvella Therapeutics news (Ticker: PVLA), a resource for investors and traders seeking the latest updates and insights on Palvella Therapeutics stock.
Palvella Therapeutics, Inc. (Nasdaq: PVLA) is a clinical-stage biopharmaceutical company developing investigational topical therapies for serious, rare skin diseases and vascular malformations that currently have no FDA-approved treatments. News about Palvella often centers on progress across its QTORIN™ platform, including clinical trial milestones, regulatory designations, and pipeline expansion.
The company’s lead candidate, QTORIN™ 3.9% rapamycin anhydrous gel, is being studied in the Phase 3 SELVA trial for microcystic lymphatic malformations and in the Phase 2 TOIVA trial for cutaneous venous malformations, with additional development planned in clinically significant angiokeratomas. Updates on these programs include topline clinical results, details on trial design, and commentary from investigators and company leadership on efficacy and safety findings.
Palvella also reports news on its second product candidate, QTORIN™ pitavastatin, for disseminated superficial actinic porokeratosis, including announcements of its selection as a new QTORIN-derived therapy and plans for Phase 2 clinical evaluation. Regulatory and grant-related news, such as FDA Breakthrough Therapy, Fast Track, and Orphan Drug designations and Orphan Products Grant funding, provide additional context on how regulators view the unmet need in the company’s target indications.
Investors and observers following PVLA news can expect coverage of quarterly financial results, corporate updates, leadership appointments in areas like medical affairs and innovation, and participation in healthcare conferences. This news stream helps track how Palvella advances its investigational programs, manages its development priorities, and positions its QTORIN™ platform within the rare dermatologic disease landscape, while consistently noting that its product candidates remain investigational and unapproved.
Palvella Therapeutics (Nasdaq: PVLA) announced that the FDA has granted rolling review for its planned NDA for QTORIN™ rapamycin to treat microcystic lymphatic malformations (microcystic LMs).
The company expects to complete the NDA submission in the second half of 2026; QTORIN has Breakthrough Therapy, Fast Track and Orphan Drug designations.
ResVita Bio appointed John D. Doux, M.D., M.B.A., to its Board of Directors as the company prepares to enter the clinic with RVB-003 for Netherton Syndrome. ResVita develops topical cell therapies using living, genetically engineered bacteria to deliver continuous protein therapeutics for chronic and rare skin diseases.
Dr. Doux is a board-certified dermatologist, healthcare investment analyst, and advocate for rare skin disease therapies, with extensive board and leadership experience across dermatology-focused organizations.
Palvella Therapeutics (Nasdaq: PVLA) completed its FDA pre-NDA meeting for QTORIN™ 3.9% rapamycin gel in microcystic lymphatic malformations and remains on track to submit an NDA in the second half of 2026.
The planned NDA will rely on Phase 3 SELVA data, supportive Phase 2 results, real-world evidence, and existing Breakthrough Therapy, Orphan Drug, Fast Track designations, with no additional efficacy study planned.
Palvella Therapeutics (Nasdaq: PVLA) announced that CEO and Founder Wes Kaupinen will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference 2026 on June 9, 2026, at 8:40 a.m. ET.
A live and archived webcast will be available on Palvella's website.
Palvella Therapeutics (Nasdaq: PVLA) announced issuance of U.S. Patent No. 12,636,273, exclusively licensed from Yale, covering topical HMG-CoA reductase inhibitors, including pitavastatin, for porokeratosis, including DSAP, with protection into 2043.
The patent strengthens IP around investigational therapy QTORIN™ pitavastatin, which targets the mevalonate pathway in affected skin. Palvella also has a pending application for its QTORIN-derived formulations and plans a Phase 2 DSAP trial in H2 2026.
Palvella Therapeutics (Nasdaq: PVLA), a clinical-stage biopharma company focused on rare skin diseases and vascular malformations with no FDA-approved therapies, was named Healthcare & Life Sciences Company of the Year at the 2026 PACT Ecosystem Awards.
The award recognizes innovation, clinical and commercial progress, capital formation, and commitment to the Greater Philadelphia life sciences community.
Palvella Therapeutics (Nasdaq: PVLA) reported new data from Phase 3 SELVA and Phase 2 TOIVA trials of QTORIN™ rapamycin for microcystic lymphatic malformations and cutaneous venous malformations.
SELVA showed high responder rates, strong patient satisfaction, and 48% of maximum possible improvement, while TOIVA demonstrated significant, durable lesion reductions. Palvella targets an NDA in 2H 2026.
Palvella Therapeutics (Nasdaq: PVLA) reported new Phase 2 TOIVA data for topical QTORIN™ rapamycin in cutaneous venous malformations (VMs), presented at the 83rd Society for Investigative Dermatology meeting.
Among patients with baseline bleeding (n=4), cVM-IGA Bleeding improved by +2.5 points (p=0.003) and 100% were "satisfied" or "very satisfied" with treatment at Week 12. Baseline qualitative interviews highlighted substantial physical, functional, and psychosocial burden. Palvella notes QTORIN rapamycin could potentially become the first FDA-approved therapy for an estimated 75,000+ U.S. patients with cutaneous VMs.
Palvella Therapeutics (Nasdaq: PVLA) received approval to transfer its common stock listing from the Nasdaq Capital Market to the Nasdaq Global Market, effective at the opening of trading on May 13, 2026.
The move reflects satisfaction of the Global Market’s higher listing standards. Shares will continue trading under the PVLA ticker, and no action is required from existing shareholders.
Palvella Therapeutics (Nasdaq: PVLA) reported Q1 2026 results and a corporate update highlighting clinical progress and strengthened liquidity. Key items: FDA pre-NDA meeting granted for QTORIN rapamycin in microcystic lymphatic malformations (meeting expected Q2 2026) with NDA submission on track for H2 2026.
Company completed an upsized $230.0 million equity financing and held $261.9 million cash and short-term investments as of March 31, 2026. Multiple trials and presentations scheduled through 2027; European patent issued covering compositions through 2038.